NCT01394211 - Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2011

Primary Completion Date

April 12, 2012

Study Completion Date

April 12, 2012

Conditions

Estrogen Receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMale Breast CancerRecurrent Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer

Interventions

DRUG

anastrozole

Given PO

DRUG

pazopanib hydrochloride

Given PO

PROCEDURE

therapeutic conventional surgery

Undergo definitive surgery

Trial Locations (1)

85724-5024

Arizona Cancer Center, Tucson